Humacyte Inc Overview
Industry: Biotechnology
Sector: Healthcare
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platfo Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Humacyte Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Cash was $19.5M.
Cash
$19.5M
reported
What changed
- Review the SEC source filing for the full reported results and management commentary.
Guidance / outlook
we expect to continue to incur losses for the foreseeable future and may never be profitable.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
HUMA260821C00000500 Interactive Stock Chart | HUMA Aug 2026 0.500 call Stock
Headline from Yahoo Finance: HUMA260821C00000500 Interactive Stock Chart | HUMA Aug 2026 0.500 call Stock.
When others don't give you opportunities, create your own: Actor Huma Qureshi
Headline from Forbes India: When others don't give you opportunities, create your own: Actor Huma Qureshi.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Headline from Yahoo Finance Singapore: Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Headline from Yahoo Finance: Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Headline from Yahoo Finance: Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Headline from Yahoo Finance Singapore: Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights.
Earnings Per Share
Score 2.00/5
Humacyte Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 2.03/5
Humacyte Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.21/5
Humacyte Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.91/5
Humacyte Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios